Items where authors include "Marks, D.I."

Article

Ghorashian, S. orcid.org/0000-0002-1555-2946, Sanderson, R. orcid.org/0000-0003-4915-2833, Lee, J. et al. (6 more authors) (2025) Position statement from the British Society of Blood and Marrow Transplantation and Cellular Therapy on insertional oncogenesis in gene‐engineered advanced cell therapy products for treatment of haematological disorders. British Journal of Haematology. ISSN 0007-1048

Patel, B., Kirkwood, A.A., Rowntree, C.J. et al. (13 more authors) (2024) Results from UKALL60+, a phase 2 study in older patients with untreated acute lymphoblastic leukemia. HemaSphere, 8 (6). e88. ISSN 2572-9241

Creasey, T., Barretta, E., Ryan, S.L. et al. (15 more authors) (2022) Genetic and genomic analysis of acute lymphoblastic leukaemia in older adults reveals a distinct profile of abnormalities: analysis of 210 patients from the UKALL14 and UKALL60+ clinical trials. Haematologica, 107 (9). pp. 2051-2063. ISSN 0390-6078

Marks, D.I., Clifton-Hadley, L., Copland, M. et al. (12 more authors) (2022) In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial. The Lancet Haematology, 9 (4). e276-e288. ISSN 2352-3026

Galleu, A., Milojkovic, D., Deplano, S. et al. (21 more authors) (2019) Mesenchymal stromal cells for acute graft-versus-host disease: response at 1 week predicts probability of survival. British Journal of Haematology, 185 (1). pp. 89-92. ISSN 0007-1048

Morley, N.J. and Marks, D.I. (2016) Inotuzumab ozogamicin in the management of acute lymphoblastic leukaemia. Expert Review of Anticancer Therapy, 16 (2). pp. 159-164. ISSN 1473-7140